Immunological recovery and antiretroviral therapy in HIV-1 infection (Q36456559)

14 August 2017

1 reference

title

Immunological recovery and antiretroviral therapy in HIV-1 infection (English)

1 reference

14 August 2017

0 references

anti-retroviral agent

0 references

2

Reto Nüesch

0 references

Manuel Battegay

series ordinal

1

object named as

Manuel Battegay

1 reference

14 August 2017

3

Bernard Hirschel

1 reference

14 August 2017

Reto Nüesch

2

1 reference

PubMed ID

16631548

14 August 2017

Gilbert R Kaufmann

series ordinal

4

1 reference

PubMed ID

16631548

14 August 2017

language of work or name

1 reference

1 May 2006

1 reference

Lancet Infectious Diseases

14 August 2017

1 reference

14 August 2017

6

1 reference

14 August 2017

5

1 reference

14 August 2017

280-287

1 reference

HIV viral load markers in clinical practice

14 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970463-7

7 January 2021

Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. Veterans Affairs Cooperative Study Group on AIDS.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970463-7

7 January 2021

Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970463-7

7 January 2021

A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970463-7

7 January 2021

Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study. Swiss HIV Cohort Study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970463-7

7 January 2021

Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970463-7

7 January 2021

Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970463-7

7 January 2021

Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970463-7

7 January 2021

Characteristics, Determinants, and Clinical Relevance of CD4 T Cell Recovery to <500 Cells/ L in HIV Type 1--Infected Individuals Receiving Potent Antiretroviral Therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970463-7

7 January 2021

Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970463-7

7 January 2021

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970463-7

7 January 2021

Decline in the AIDS and death rates in the EuroSIDA study: an observational study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970463-7

7 January 2021

Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970463-7

7 January 2021

Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970463-7

7 January 2021

Alterations in the immune response of human immunodeficiency virus (HIV)-infected subjects treated with an HIV-specific protease inhibitor, ritonavir

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970463-7

7 January 2021

Prolonged suppression of human immunodeficiency virus type 1 (HIV-1) viremia in persons with advanced disease results in enhancement of CD4 T cell reactivity to microbial antigens but not to HIV-1 antigens.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970463-7

7 January 2021

Discontinuation of primary prophylaxis for Pneumocystis carinii pneumonia and toxoplasmic encephalitis in human immunodeficiency virus type I-infected patients: the changes in opportunistic prophylaxis study.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970463-7

7 January 2021

Discontinuation of Primary Prophylaxis againstPneumocystis cariniiPneumonia in HIV-1–Infected Adults Treated with Combination Antiretroviral Therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970463-7

7 January 2021

Discontinuation of chemoprophylaxis against Pneumocystis carinii pneumonia in patients with HIV infection. HIV Outpatient Study (HOPS) Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970463-7

7 January 2021

Discontinuation of prophylaxis for Pneumocystis carinii pneumonia in HIV-1-infected patients treated with highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970463-7

7 January 2021

Discontinuation of Pneumocystis carinii pneumonia prophylaxis after start of highly active antiretroviral therapy in HIV-1 infection. EuroSIDA Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970463-7

7 January 2021

Can chemoprophylaxis against opportunistic infections be discontinued after an increase in CD4 cells induced by highly active antiretroviral therapy?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970463-7

7 January 2021

Safe Interruption of Maintenance Therapy against Previous Infection with Four Common HIV-Associated Opportunistic Pathogens during Potent Antiretroviral Therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970463-7

7 January 2021

Discontinuation of prophylaxis against Mycobacterium avium complex disease in HIV-infected patients who have a response to antiretroviral therapy. Terry Beirn Community Programs for Clinical Research on AIDS

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970463-7

7 January 2021

Discontinuation of secondary prophylaxis for opportunistic infections in HIV-infected patients receiving highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970463-7

7 January 2021

A Randomized Trial of the Discontinuation of Primary and Secondary Prophylaxis againstPneumocystis cariniiPneumonia after Highly Active Antiretroviral Therapy in Patients with HIV Infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970463-7

7 January 2021

Risk for preventable opportunistic infections in persons with AIDS after antiretroviral therapy increases CD4+ T lymphocyte counts above prophylaxis thresholds

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970463-7

7 January 2021

Discontinuation of Mycobacterium avium complex prophylaxis in patients with antiretroviral therapy-induced increases in CD4+ cell count. A randomized, double-blind, placebo-controlled trial. AIDS Clinical Trials Group 362 Study Team.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970463-7

7 January 2021

Discontinuation of maintenance therapy in patients with quiescent cytomegalovirus retinitis and elevated CD4+ counts.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970463-7

7 January 2021

Lack of reactivation of cytomegalovirus (CMV) retinitis after stopping CMV maintenance therapy in AIDS patients with sustained elevations in CD4 T cells in response to highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970463-7

7 January 2021

Discontinuation of anticytomegalovirus therapy in patients with HIV infection and cytomegalovirus retinitis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970463-7

7 January 2021

Discontinuing anticytomegalovirus therapy in patients with immune reconstitution after combination antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970463-7

7 January 2021

Discontinuation of secondary prophylaxis for cryptococcal meningitis in human immunodeficiency virus-infected patients treated with highly active antiretroviral therapy: a prospective, multicenter, randomized study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970463-7

7 January 2021

Discontinuation of maintenance therapy for cytomegalovirus retinitis in HIV-infected patients receiving highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970463-7

7 January 2021

Nadir CD4+ T-cell count and numbers of CD28+ CD4+ T-cells predict functional responses to immunizations in chronic HIV-1 infection.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970463-7

7 January 2021

Determinants of paradoxical CD4 cell reconstitution after protease inhibitor-containing antiretroviral regimen

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970463-7

7 January 2021

CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970463-7

7 January 2021

Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970463-7

7 January 2021

Initial increase in blood CD4(+) lymphocytes after HIV antiretroviral therapy reflects redistribution from lymphoid tissues.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970463-7

7 January 2021

Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection: a composite of redistribution and proliferation.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970463-7

7 January 2021

Long-term immunological response in HIV-1-infected subjects receiving potent antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970463-7

7 January 2021

Rapid restoration of CD4 T cell subsets in subjects receiving antiretroviral therapy during primary HIV-1 infection.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970463-7

7 January 2021

The extent of HIV-1-related immunodeficiency and age predict the long-term CD4 T lymphocyte response to potent antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970463-7

7 January 2021

Influence of age on CD4 cell recovery in human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy: evidence from the EuroSIDA study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970463-7

7 January 2021

T cell dynamics in HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970463-7

7 January 2021

Persistent apoptosis in HIV-1-infected individuals receiving potent antiretroviral therapy is associated with poor recovery of CD4 T lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970463-7

7 January 2021

Persistent GB virus C infection and survival in HIV-infected men.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970463-7

7 January 2021

Infection with GB virus C and reduced mortality among HIV-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970463-7

7 January 2021

Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970463-7

7 January 2021

HIV and hepatitis C virus co-infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970463-7

7 January 2021

Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970463-7

7 January 2021

The modern ART of HIV infection management: towards a tailored approach to maximize CD4 T cell reconstitution.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970463-7

7 January 2021

HIV preferentially infects HIV-specific CD4+ T cells

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970463-7

7 January 2021

Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970463-7

7 January 2021

Interruption of treatment with individual therapeutic drug classes in adults with multidrug-resistant HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970463-7

7 January 2021

HIV-1 drug resistance evolution among patients on potent combination antiretroviral therapy with detectable viremia.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970463-7

7 January 2021

Reduction of HIV-1 in blood and lymph nodes following potent antiretroviral therapy and the virologic correlates of treatment failure.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970463-7

7 January 2021

Durable HIV treatment benefit despite low-level viremia: reassessing definitions of success or failure.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970463-7

7 January 2021

Induction of prolonged survival of CD4+ T lymphocytes by intermittent IL-2 therapy in HIV-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970463-7

7 January 2021

The evaluation of subcutaneous proleukin (interleukin-2) in a randomized international trial: rationale, design, and methods of ESPRIT.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970463-7

7 January 2021

Early virological failure in treatment-naive HIV-infected adults receiving didanosine and tenofovir plus efavirenz or nevirapine

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970463-7

7 January 2021

Dose-dependent influence of didanosine on immune recovery in HIV-infected patients treated with tenofovir

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970463-7

7 January 2021

Clinical management of treatment-experienced, HIV-infected patients with the fusion inhibitor enfuvirtide: consensus recommendations

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970463-7

7 January 2021

In vitro toxicity of 3′‐azido‐3′‐deoxythymidine, carbovir and 2′, 3′‐didehydro‐2′, 3′‐dideoxythymidine to human and murine haematopoietic progenitor cells

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970463-7

7 January 2021

Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970463-7

7 January 2021

Assessment of a pilot antiretroviral drug therapy programme in Uganda: patients' response, survival, and drug resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970463-7

7 January 2021

HIV disease progression in a patient cohort treated via a clinical research network in a resource limited setting

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970463-7

7 January 2021

Control of HIV despite the Discontinuation of Antiretroviral Therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970463-7

7 January 2021

HIV-1 rebound during interruption of highly active antiretroviral therapy has no deleterious effect on reinitiated treatment. Comet Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970463-7

7 January 2021

HIV-1-specific immune responses in subjects who temporarily contain virus replication after discontinuation of highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970463-7

7 January 2021

Immune control of HIV-1 after early treatment of acute infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970463-7

7 January 2021

Control of SIV rebound through structured treatment interruptions during early infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970463-7

7 January 2021

Stimulation of HIV-specific cellular immunity by structured treatment interruption fails to enhance viral control in chronic HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970463-7

7 January 2021

A prospective trial of structured treatment interruptions in human immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970463-7

7 January 2021

Short-cycle structured intermittent treatment of chronic HIV infection with highly active antiretroviral therapy: effects on virologic, immunologic, and toxicity parameters

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970463-7

7 January 2021

Failures of 1 week on, 1 week off antiretroviral therapies in a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970463-7

7 January 2021

A prospective, randomized trial of structured treatment interruption for patients with chronic HIV type 1 infection.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970463-7

7 January 2021

Biphasic decline of CD4 cell count during scheduled treatment interruptions

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970463-7

7 January 2021

Development of HIV with drug resistance after CD4 cell count-guided structured treatment interruptions in patients treated with highly active antiretroviral therapy after dual-nucleoside analogue treatment.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970463-7

7 January 2021

Virological and immunological effects of treatment interruptions in HIV-1 infected patients with treatment failure

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970463-7

7 January 2021

No evidence for persistence of multidrug-resistant viral strains after a 7-month treatment interruption in an HIV-1-infected individual

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970463-7

7 January 2021

Benefit of treatment interruption in HIV-infected patients with multiple therapeutic failures

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970463-7

7 January 2021

Structured treatment interruption in patients with multidrug-resistant human immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970463-7

7 January 2021

Immune restoration disease after the treatment of immunodeficient HIV-infected patients with highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970463-7

7 January 2021

Immune restoration disease after antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970463-7

7 January 2021

Immune reconstitution disease associated with mycobacterial infections in HIV-infected individuals receiving antiretrovirals

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970463-7

7 January 2021

Immune reconstitution in HIV-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970463-7

7 January 2021

Immune reconstitution inflammatory syndrome: emergence of a unique syndrome during highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970463-7

7 January 2021

Clinical indicators of immune restoration following highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970463-7

7 January 2021

Tuberculosis in HIV-infected patients: a comprehensive review.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970463-7

7 January 2021

Determinants of immune reconstitution inflammatory syndrome in HIV type 1-infected patients with tuberculosis after initiation of antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970463-7

7 January 2021

Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: analysis of prospective studies

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970463-7

7 January 2021

Clinical spectrum of the immune restoration inflammatory syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970463-7

7 January 2021

10.1016/S1473-3099(06)70463-7

Identifiers

DOI

1 reference

14 August 2017

1 reference

PubMed ID

16631548